SOURCE: XenaCare Holdings, Inc

XenaCare Holdings, Inc

August 31, 2010 08:26 ET

XenaCare Announces Cobroxin to Be Featured on the "Medical Minute" Television Vignettes

BOCA RATON, FL--(Marketwire - August 31, 2010) -  (OTCBB: XCHO) -- This fall, Cobroxin advisor Dr. Bob Arnot will feature Cobroxin on his "Medical Minute" themed vignettes. In each "Medical Minute" segment, Dr. Bob Arnot examines diseases and medical conditions, including global health initiatives. The "Medical Minute" vignettes featuring Cobroxin are scheduled to air during local television newscasts as part of Meredith Corporation's "Better" show. The Show coverage currently reaches 60 million households in 75 Markets. This includes 6 of the top 10 markets.

About Dr. Bob Arnot: Dr. Bob Arnot is a physician and international humanitarian with a hunger for knowledge and a desire to introduce audiences to important issues around the world. Arnot is one of the most recognized names in medical and health professions, having served as the former chief medical editor and special foreign correspondent for NBC News. For his work in the media, Arnot has won an Alfred I. DuPont Award for his insider's look at the use and abuse of crack cocaine for the program "48 Hours on Crack Street," and an Overseas Press Club Award for NBC's team coverage of the floods in Mozambique. A native of Boston, Massachusetts, Arnot received a Bachelor of Science degree from Dartmouth College in 1972 and a medical degree from McGill University. He began his medical career as the founder and chief of the Lake Placid Medical Center, where he not only served as administrator but also as the physician for the 1977-1980 US Ski Team and the 1980 Winter Olympic Games. A successful author, Arnot has published ten books, including his most recent, "Seven Steps to Stop a Heart Attack."

About Cobroxin: Until now, you would have needed a prescription strength pain reliever to get the same level of relief you get from Cobroxin. Cobroxin is non-opiate, non-narcotic, non-addictive, safe and effective. A doctor's visit is not required to purchase or use Cobroxin. XenaCare Holdings CEO, Frank Rizzo, reports, "Cobroxin has been widely accepted by the major retailers throughout the U.S. because consumers are requesting it. The current consumer testimonials have been very positive. Many of these testimonials can be read online by visiting"

Cobroxin Oral Spray is a systemic, anti-inflammatory analgesic recommended for treating lower back pain, shoulder pain, neck aches, neuralgia, migraines, cramps and other types of persistent pain. Because it may take a few days for the body to become sensitized to the product and to feel the full effect from Cobroxin, it is best to use Cobroxin as directed for at least the first week. Once the pain reaches a comfortable level, frequency of dosing can be reduced to an as needed basis.

Cobroxin gives potent pain relief to:

  • People without healthcare insurance (42 million)
  • People without prescription coverage
  • People afraid of opiate side effects
  • People subject to drug screening for work
  • People for whom OTC NSAIDs didn't work and are just living with the pain (back pain)

Cobroxin targets consumers not well-served by current product either because of cost or side effects

SEC Disclaimer
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in XenaCare Holding's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Receiving an exclusive marketing and distribution license for the treatment of chronic pain should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Contact Information

  • Contact:
    Frank Rizzo
    XenaCare Holdings, Inc.
    (561) 496-6676
    Email Contact